anurajms/meta_analysis huggingface dataset:
MESH terms:
Oscillating devices for airway clearance in people with cystic fibrosis
1. Breathing Exercises; 2. Chest Wall Oscillation [*instrumentation]; 3. Cystic Fibrosis [*complications, physiopathology]; 4. Disease Progression; 5. Forced Expiratory Flow Rates; 6. Forced Expiratory Volume; 7. Lung Diseases, Obstructive [etiology, *therapy]; 8. *Mucociliary Clearance; 9. Mucus [*metabolism]; 10. Patient Satisfaction; 11. Randomized Controlled Trials as Topic; 12. Sputum [metabolism]; 13. Vibration [*therapeutic use];
MESH terms:
Tonsillectomy versus tonsillotomy for obstructive sleep‐disordered breathing in children
1. Blood Loss, Surgical [statistics & numerical data]; 2. Pain, Postoperative [epidemiology]; 3. Palatine Tonsil [*surgery]; 4. Postoperative Complications [epidemiology]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Reoperation [statistics & numerical data]; 9. Severity of Illness Index; 10. Sleep Apnea, Obstructive [*surgery]; 11. Tonsillectomy [adverse effects, *methods];
MESH terms:
Treating progressive disseminated histoplasmosis in people living with HIV
1. Amphotericin B [adverse effects, *therapeutic use]; 2. Anti-HIV Agents [therapeutic use]; 3. Antifungal Agents [adverse effects, *therapeutic use]; 4. Cohort Studies; 5. Deoxycholic Acid; 6. Drug Administration Schedule; 7. Fluconazole [therapeutic use]; 8. Histoplasmosis [*drug therapy, mortality]; 9. HIV Infections [*complications, drug therapy]; 10. Induction Chemotherapy; 11. Itraconazole [therapeutic use]; 12. Kidney [drug effects]; 13. Liposomes; 14. Maintenance Chemotherapy; 15. Randomized Controlled Trials as Topic;
MESH terms:
Clonazepam add‐on therapy for drug‐resistant epilepsy
1. Anticonvulsants [administration & dosage, *therapeutic use]; 2. Clonazepam [administration & dosage, *therapeutic use]; 3. Drug Resistant Epilepsy [*drug therapy];
MESH terms:
Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children
1. Calcium [*therapeutic use]; 2. Fractures, Bone [epidemiology, prevention & control]; 3. Randomized Controlled Trials as Topic; 4. Rickets [etiology, *therapy]; 5. Vitamin D [*therapeutic use]; 6. Vitamin D Deficiency [complications, therapy]; 7. Vitamins [*therapeutic use];
MESH terms:
Non‐invasive respiratory support for the management of transient tachypnea of the newborn
1. Continuous Positive Airway Pressure [adverse effects, statistics & numerical data]; 2. High‐Frequency Ventilation [adverse effects, statistics & numerical data]; 3. Oxygen Inhalation Therapy [adverse effects, statistics & numerical data]; 4. Pneumothorax [etiology]; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [statistics & numerical data]; 7. Respiratory Therapy [adverse effects, *methods]; 8. Time Factors; 9. Transient Tachypnea of the Newborn [mortality, *therapy];
MESH terms:
Interventions for fatigue in inflammatory bowel disease
1. Adalimumab [administration & dosage, adverse effects]; 2. Anti‐Inflammatory Agents [administration & dosage, adverse effects]; 3. Cognitive Behavioral Therapy; 4. Electroacupuncture; 5. Exercise; 6. Fatigue [etiology, *therapy]; 7. Fatty Acids, Omega‐3 [administration & dosage, adverse effects]; 8. Ferric Compounds [adverse effects]; 9. Hematinics [adverse effects]; 10. Inflammatory Bowel Diseases [*complications]; 11. Psychotherapy, Brief; 12. Pyrones [adverse effects]; 13. Quality of Life; 14. Randomized Controlled Trials as Topic;
MESH terms:
Anthelmintic drugs for treating ascariasis
1. Albendazole [administration & dosage, therapeutic use]; 2. Anthelmintics [administration & dosage, *therapeutic use]; 3. Ascariasis [*drug therapy]; 4. Ascaris lumbricoides; 5. Ivermectin [administration & dosage, therapeutic use]; 6. Mebendazole [administration & dosage, therapeutic use]; 7. Parasite Egg Count; 8. Placebos [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Omega‐3 fatty acid supplementation for cystic fibrosis
1. *Dietary Supplements; 2. Bias; 3. Cystic Fibrosis [blood, *diet therapy]; 4. Disease Progression; 5. Fatty Acids, Omega‐3 [*administration & dosage, adverse effects]; 6. Fatty Acids, Omega‐6 [administration & dosage]; 7. Forced Expiratory Volume; 8. Olive Oil [administration & dosage]; 9. Randomized Controlled Trials as Topic; 10. Vital Capacity;
MESH terms:
Rinse‐free hand wash for reducing absenteeism among preschool and school children
1. *Absenteeism; 2. Gastrointestinal Diseases [epidemiology, prevention & control]; 3. Hand Hygiene [*methods]; 4. Preventive Medicine [methods]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Tract Diseases [epidemiology, prevention & control]; 7. Schools [statistics & numerical data];
MESH terms:
Agricultural and nutritional education interventions for reducing aflatoxin exposure to improve infant and child growth in low‐ and middle‐income countries
1. Aflatoxins [*poisoning]; 2. Agriculture [*education, methods]; 3. Breast Feeding; 4. *Developing Countries; 5. Food Contamination [*prevention & control]; 6. *Growth; 7. Kenya; 8. Prenatal Exposure Delayed Effects [prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Tanzania; 11. Thinness [prevention & control]; 12. Zimbabwe;
MESH terms:
EEG for children with complex febrile seizures
1. *Electroencephalography; 2. *Seizures, Febrile; 3. Time Factors;
MESH terms:
Clonidine for pain in non‐ventilated infants
1. Analgesics [*therapeutic use]; 2. Clonidine [*therapeutic use]; 3. Pain, Postoperative [*prevention & control]; 4. Pain, Procedural [*drug therapy, prevention & control];
MESH terms:
Early versus late parenteral nutrition for critically ill term and late preterm infants
1. Amino Acids [administration & dosage, adverse effects]; 2. Bias; 3. Critical Illness [*therapy]; 4. Cross Infection [epidemiology]; 5. Fat Emulsions, Intravenous [administration & dosage, adverse effects]; 6. Hospital Mortality; 7. Hypoglycemia [epidemiology]; 8. Infant Mortality; 9. Infant, Premature; 10. Length of Stay; 11. Lipids [administration & dosage, adverse effects]; 12. Parenteral Nutrition [adverse effects, mortality, *statistics & numerical data]; 13. Parenteral Nutrition Solutions [administration & dosage, adverse effects]; 14. Randomized Controlled Trials as Topic; 15. Respiration, Artificial [statistics & numerical data]; 16. Term Birth; 17. Time Factors;
MESH terms:
Exercise versus no exercise for the occurrence, severity, and duration of acute respiratory infections
1. *Exercise; 2. Acute Disease; 3. Bicycling; 4. Randomized Controlled Trials as Topic; 5. Respiratory Tract Infections [epidemiology, *prevention & control]; 6. Severity of Illness Index; 7. Time Factors; 8. Walking;
MESH terms:
Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation
1. *Burkholderia cepacia complex; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Burkholderia Infections [*drug therapy, microbiology]; 4. Cystic Fibrosis [*complications]; 5. Disease Progression;
MESH terms:
Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)
1. *Patient Safety; 2. Case‐Control Studies; 3. Cohort Studies; 4. Death, Sudden [etiology, *prevention & control]; 5. Epilepsy [*complications]; 6. Epilepsy, Tonic‐Clonic [complications, prevention & control]; 7. Monitoring, Physiologic [methods]; 8. Quality of Life; 9. Sleep;
MESH terms:
Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants
1. Administration, Oral; 2. Bacterial Infections [epidemiology, prevention & control]; 3. Cause of Death; 4. Chronic Disease; 5. *Enteral Nutrition; 6. Enterocolitis, Necrotizing [epidemiology, *prevention & control]; 7. Infant, Premature; 8. Infant, Premature, Diseases [*prevention & control]; 9. Lacticaseibacillus rhamnosus; 10. Lactoferrin [*administration & dosage]; 11. Lung Diseases [epidemiology]; 12. Mycoses [epidemiology, prevention & control]; 13. Numbers Needed To Treat; 14. Probiotics [*administration & dosage]; 15. Randomized Controlled Trials as Topic; 16. Retinopathy of Prematurity [epidemiology]; 17. Sepsis [*prevention & control];
MESH terms:
Interventions for preventing and managing advanced liver disease in cystic fibrosis
1. Cystic Fibrosis [*complications, genetics]; 2. Cystic Fibrosis Transmembrane Conductance Regulator [genetics]; 3. Gastrointestinal Hemorrhage [prevention & control]; 4. Hypertension, Portal [prevention & control]; 5. Liver Diseases [etiology, prevention & control, *therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Physical therapies for postural abnormalities in people with cystic fibrosis
1. *Pain Management; 2. *Physical Therapy Modalities; 3. *Quality of Life; 4. Cystic Fibrosis [*physiopathology]; 5. Posture; 6. Randomized Controlled Trials as Topic;
MESH terms:
Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia
1. Adrenal Hyperplasia, Congenital [*drug therapy]; 2. Dexamethasone; 3. Glucocorticoids [*therapeutic use]; 4. Prednisolone; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Sustained versus standard inflations during neonatal resuscitation to prevent mortality and improve respiratory outcomes
1. Cerebral Intraventricular Hemorrhage [epidemiology]; 2. Ductus Arteriosus, Patent [drug therapy, epidemiology]; 3. Heart Massage; 4. Hospital Mortality; 5. Intubation, Intratracheal [methods, mortality]; 6. Lung Diseases [epidemiology]; 7. Pneumothorax [epidemiology]; 8. Positive‐Pressure Respiration [instrumentation, *methods, mortality]; 9. Pulmonary Surfactants [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Respiration, Artificial [statistics & numerical data]; 12. Resuscitation [*methods]; 13. Time Factors;
MESH terms:
Diaphragm‐triggered non‐invasive respiratory support in preterm infants
1. Continuous Positive Airway Pressure; 2. Diaphragm [*physiology]; 3. *Infant, Premature; 4. Interactive Ventilatory Support; 5. Intermittent Positive-Pressure Ventilation; 6. Randomized Controlled Trials as Topic;
MESH terms:
Postnatal corticosteroids for transient tachypnoea of the newborn
1. Adrenal Cortex Hormones [*therapeutic use]; 2. Budesonide [therapeutic use]; 3. Cesarean Section; 4. Infant, Premature; 5. Oxygen Inhalation Therapy; 6. Randomized Controlled Trials as Topic; 7. Respiration, Artificial; 8. Transient Tachypnea of the Newborn [*drug therapy];
MESH terms:
Immunosuppressive agents for treating IgA nephropathy
1. Calcineurin Inhibitors [adverse effects, therapeutic use]; 2. Cause of Death; 3. Confidence Intervals; 4. Creatinine [blood]; 5. Drug Administration Schedule; 6. Drug Therapy, Combination; 7. Glomerular Filtration Rate [drug effects]; 8. Glomerulonephritis, IGA [*drug therapy]; 9. Immunosuppressive Agents [adverse effects, *therapeutic use]; 10. Kidney Failure, Chronic [mortality, prevention & control, therapy]; 11. Leflunomide [adverse effects, therapeutic use]; 12. Mycophenolic Acid [adverse effects, therapeutic use]; 13. Proteinuria [drug therapy]; 14. Randomized Controlled Trials as Topic; 15. Remission Induction; 16. Ribonucleosides [adverse effects, therapeutic use]; 17. Risk; 18. Steroids [administration & dosage, adverse effects, *therapeutic use];
MESH terms:
Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. End Stage Liver Disease [*complications]; 2. Esophageal and Gastric Varices [complications]; 3. Gastrointestinal Hemorrhage [*prevention & control]; 4. Hypertension, Portal [*complications]; 5. Ligation [methods]; 6. Portal Vein; 7. Primary Prevention; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Sclerotherapy [*methods]; 11. Venous Thrombosis [*complications];
MESH terms:
Probiotics for maintenance of remission in ulcerative colitis
1. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 2. Colitis, Ulcerative [*therapy]; 3. Mesalamine [therapeutic use]; 4. Probiotics [adverse effects, *therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Remission Induction;
MESH terms:
Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age
1. Avitaminosis [prevention & control]; 2. Deficiency Diseases; 3. Dietary Supplements; 4. *Food, Fortified; 5. Infant Nutritional Physiological Phenomena [*physiology]; 6. Micronutrients [*administration & dosage, deficiency]; 7. Nutritional Status; 8. Randomized Controlled Trials as Topic; 9. Trace Elements [administration & dosage]; 10. Vitamins [*administration & dosage];
MESH terms:
Timing of hypertonic saline inhalation for cystic fibrosis
1. *Mucociliary Clearance; 2. Administration, Inhalation; 3. Cystic Fibrosis [*drug therapy]; 4. Drug Administration Schedule; 5. Saline Solution, Hypertonic [administration & dosage, *therapeutic use]; 6. Sputum [metabolism];
MESH terms:
Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization
1. Anticoagulants [*administration & dosage]; 2. Cardiac Catheterization [*adverse effects]; 3. Hemorrhage [chemically induced]; 4. Heparin [*administration & dosage]; 5. Infusions, Intravenous [methods]; 6. Peripheral Arterial Disease [*prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Thrombosis [*prevention & control];
MESH terms:
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants
1. *Infant, Low Birth Weight; 2. Cyclooxygenase Inhibitors [therapeutic use]; 3. Ductus Arteriosus, Patent [*drug therapy]; 4. Enzyme Inhibitors [adverse effects, therapeutic use]; 5. Ibuprofen [adverse effects, *therapeutic use]; 6. Indomethacin [adverse effects, therapeutic use]; 7. Infant, Premature; 8. Randomized Controlled Trials as Topic;
MESH terms:
Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants
1. Anemia, Neonatal [blood, prevention & control]; 2. Epoetin Alfa; 3. Erythrocyte Transfusion [*statistics & numerical data]; 4. Erythropoietin [*administration & dosage, adverse effects, blood]; 5. Infant, Low Birth Weight [*blood]; 6. Infant, Premature [*blood]; 7. Randomized Controlled Trials as Topic; 8. Retinopathy of Prematurity [blood, prevention & control];
MESH terms:
Surfactant for pulmonary haemorrhage in neonates
1. *Infant, Premature; 2. Hemorrhage [*drug therapy]; 3. Lung Diseases [*drug therapy]; 4. Pulmonary Surfactants [*therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants
1. Cross Infection [*prevention & control]; 2. IgG Deficiency [drug therapy]; 3. Immunoglobulin G [*administration & dosage, therapeutic use]; 4. Immunoglobulins, Intravenous [therapeutic use]; 5. Infant, Low Birth Weight [immunology]; 6. Infant, Premature [immunology]; 7. Infant, Premature, Diseases [*prevention & control]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Paracetamol (acetaminophen) for prevention or treatment of pain in newborns
1. Acetaminophen [*therapeutic use]; 2. Analgesics, Non‐Narcotic [*therapeutic use]; 3. Pain [*drug therapy, prevention & control]; 4. Pain Management; 5. Randomized Controlled Trials as Topic;
MESH terms:
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis
1. Colitis, Ulcerative [*drug therapy]; 2. Janus Kinase Inhibitors [*therapeutic use]; 3. Maintenance Chemotherapy; 4. Piperidines [*therapeutic use]; 5. Protein Kinase Inhibitors; 6. Pyrimidines [*therapeutic use]; 7. Pyrroles [*therapeutic use]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for chronic pruritus of unknown origin
1. Aging [pathology]; 2. Emollients [*therapeutic use]; 3. Phototherapy; 4. Pruritus [drug therapy, etiology, *therapy]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Severity of Illness Index; 8. Skin Care [*methods]; 9. Skin Cream [*therapeutic use]; 10. Treatment Outcome;
MESH terms:
Probiotics for people with cystic fibrosis
1. Cystic Fibrosis [complications, *microbiology, *therapy]; 2. Leukocyte L1 Antigen Complex [*analysis]; 3. Probiotics [*therapeutic use]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Improving vaccination uptake among adolescents
1. Controlled Before‐After Studies; 2. Health Education [*methods]; 3. Health Personnel [education]; 4. Parents [education]; 5. Randomized Controlled Trials as Topic; 6. Vaccination [*statistics & numerical data, trends];
MESH terms:
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury
1. Brain Injuries [*complications]; 2. Brain Injuries, Traumatic [*complications]; 3. Glasgow Outcome Scale; 4. Intracranial Hypertension [*drug therapy]; 5. Intracranial Pressure [*drug effects]; 6. Randomized Controlled Trials as Topic; 7. Saline Solution, Hypertonic [*therapeutic use];
MESH terms:
Anti‐inflammatory medications for obstructive sleep apnoea in children
1. Acetates; 2. Adenoidectomy; 3. Anti‐Inflammatory Agents [*therapeutic use]; 4. Cyclopropanes; 5. Quinolines; 6. Randomized Controlled Trials as Topic; 7. Sleep Apnea, Obstructive [*drug therapy]; 8. Sulfides; 9. Tonsillectomy;
MESH terms:
Sclerotherapy versus beta‐blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis
1. Adrenergic beta-Antagonists [therapeutic use]; 2. Esophageal and Gastric Varices [*therapy]; 3. Gastrointestinal Hemorrhage [*prevention & control]; 4. Ligation; 5. Liver Cirrhosis [complications]; 6. Portal Vein; 7. Primary Prevention; 8. Randomized Controlled Trials as Topic; 9. *Sclerotherapy; 10. Venous Thrombosis [complications];
MESH terms:
Topical antiseptics for chronic suppurative otitis media
1. Administration, Topical; 2. Anti‐Infective Agents, Local [administration & dosage, *therapeutic use]; 3. Chronic Disease; 4. Otitis Media, Suppurative [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Drug treatment for spinal muscular atrophy types II and III
1. Amines [therapeutic use]; 2. Creatine [therapeutic use]; 3. Cyclohexanecarboxylic Acids [therapeutic use]; 4. gamma-Aminobutyric Acid [therapeutic use]; 5. Hydroxyurea [therapeutic use]; 6. Neuroprotective Agents [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Spinal Muscular Atrophies of Childhood [*drug therapy]; 9. Thyrotropin-Releasing Hormone [therapeutic use];
MESH terms:
Antibiotics versus topical antiseptics for chronic suppurative otitis media
1. Administration, Topical; 2. Anti-Bacterial Agents [*therapeutic use]; 3. Anti-Infective Agents, Local [*therapeutic use]; 4. Otitis Media, Suppurative [*drug therapy]; 5. Quinolones [therapeutic use]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Caregiver involvement in interventions for improving children's dietary intake and physical activity behaviors
1. Caregivers; 2. Child Nutritional Physiological Phenomena [*physiology]; 3. *Diet; 4. Eating; 5. Energy Intake; 6. Exercise [*physiology]; 7. Fruit; 8. *Health Behavior; 9. *Parents; 10. Pediatric Obesity [prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Vegetables;
MESH terms:
Topical antibiotics for chronic suppurative otitis media
1. Administration, Topical; 2. Anti‐Bacterial Agents [administration & dosage, *therapeutic use]; 3. Chronic Disease; 4. Otitis Media, Suppurative [complications, *drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Decompressive craniectomy for the treatment of high intracranial pressure in closed traumatic brain injury
1. Brain Injuries, Traumatic [*complications]; 2. Decompressive Craniectomy [*methods]; 3. Intracranial Hypertension [*surgery]; 4. Intracranial Pressure; 5. Randomized Controlled Trials as Topic;
MESH terms:
Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA)
1. Adenoidectomy [methods]; 2. Fever [surgery]; 3. Lymphadenitis [*surgery]; 4. Periodicity; 5. Pharyngitis [*surgery]; 6. Randomized Controlled Trials as Topic; 7. Stomatitis, Aphthous [*surgery]; 8. Syndrome; 9. Tonsillectomy [*methods];
MESH terms:
Racecadotril for acute diarrhoea in children
1. Diarrhea [*drug therapy]; 2. Fluid Therapy; 3. Length of Stay; 4. Randomized Controlled Trials as Topic; 5. Thiorphan [*analogs & derivatives, therapeutic use]; 6. Treatment Outcome;
MESH terms:
Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
1. Immunization Schedule; 2. Injections, Intradermal; 3. Injections, Intramuscular; 4. Poliomyelitis [*prevention & control]; 5. Poliovirus [*immunology]; 6. Poliovirus Vaccine, Inactivated [administration & dosage, immunology]; 7. Poliovirus Vaccine, Oral [*administration & dosage, immunology]; 8. Randomized Controlled Trials as Topic; 9. Vaccination [methods];
MESH terms:
Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis
1. *Pseudomonas aeruginosa; 2. Administration, Inhalation; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Cystic Fibrosis [*complications]; 5. Forced Expiratory Volume; 6. Pseudomonas Infections [*complications, drug therapy, *prevention & control]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Secondary Prevention; 11. Tobramycin [therapeutic use];
MESH terms:
Prophylactic antibiotics for penetrating abdominal trauma: duration of use and antibiotic choice
1. *Antibiotic Prophylaxis; 2. Abdominal Injuries [complications, *drug therapy]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Time Factors; 6. Wound Infection [*prevention & control]; 7. Wounds, Penetrating [complications, *drug therapy];
MESH terms:
Interventions for managing halitosis
1. Chewing Gum; 2. Chlorhexidine [therapeutic use]; 3. Dental Scaling; 4. Halitosis [*therapy]; 5. Mouthwashes [*therapeutic use]; 6. Oral Health; 7. Oral Hygiene [*methods]; 8. Randomized Controlled Trials as Topic; 9. Tongue [microbiology]; 10. Toothbrushing [methods]; 11. Toothpastes;
MESH terms:
Drug treatment for spinal muscular atrophy type I
1. Neuroprotective Agents [*therapeutic use]; 2. Oligonucleotides [*therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Spinal Muscular Atrophies of Childhood [*drug therapy];
MESH terms:
Iron therapy for preoperative anaemia
1. *Preoperative Care; 2. Anemia, Iron‐Deficiency [prevention & control, *therapy]; 3. Iron, Dietary [*administration & dosage]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Primary closure versus delayed or no closure for traumatic wounds due to mammalian bite
1. *Bites and Stings; 2. *Wound Healing; 3. Randomized Controlled Trials as Topic; 4. Soft Tissue Injuries [*therapy]; 5. Wound Infection [*epidemiology, prevention & control];
MESH terms:
Corticosteroids for treating sepsis in children and adults
1. Adrenal Cortex Hormones [adverse effects, *therapeutic use]; 2. Hospital Mortality; 3. Length of Stay; 4. Randomized Controlled Trials as Topic; 5. Risk Factors; 6. Sepsis [*drug therapy, *mortality]; 7. Time Factors;
MESH terms:
Beginning reading interventions for children and adolescents with intellectual disability
1. *Education of Intellectually Disabled; 2. *Reading; 3. Intellectual Disability [*psychology]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis
1. Adverse Drug Reaction Reporting Systems; 2. Immunity, Mucosal; 3. Immunization Schedule; 4. Interrupted Time Series Analysis; 5. Poliomyelitis [*prevention & control]; 6. Poliovirus [immunology]; 7. Poliovirus Vaccine, Inactivated [*administration & dosage, *adverse effects]; 8. Poliovirus Vaccine, Oral [*administration & dosage, *adverse effects]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Parent training programmes for managing infantile colic
1. Colic [*therapy]; 2. Parents [*education, psychology]; 3. Randomized Controlled Trials as Topic; 4. Stress, Psychological;
MESH terms:
Intravenous immunoglobulins for epilepsy
1. Anticonvulsants [therapeutic use]; 2. Epilepsy [*drug therapy]; 3. Immunoglobulins, Intravenous [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Seizures [drug therapy]; 6. Treatment Outcome;
MESH terms:
Video feedback for parental sensitivity and attachment security in children under five years
1. *Child Development; 2. *Emotions; 3. *Object Attachment; 4. Child Rearing; 5. Parents [*psychology]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis
1. Cystic Fibrosis [complications, *therapy]; 2. Drainage, Postural [methods]; 3. Forced Expiratory Volume; 4. Mucociliary Clearance; 5. Mucus [metabolism]; 6. Physical Therapy Modalities; 7. Positive‐Pressure Respiration [*methods]; 8. Randomized Controlled Trials as Topic; 9. Respiratory Therapy [*methods];
MESH terms:
Fluorides for preventing early tooth decay (demineralised lesions) during fixed brace treatment
1. Cariostatic Agents [administration & dosage, *therapeutic use]; 2. Dental Caries [*prevention & control]; 3. Fluorides [administration & dosage, *therapeutic use]; 4. Mouthwashes [therapeutic use]; 5. Orthodontic Brackets [*adverse effects]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Human milk‐derived fortifier versus bovine milk‐derived fortifier for prevention of mortality and morbidity in preterm neonates
1. *Infant Nutritional Physiological Phenomena; 2. Cattle; 3. Enterocolitis, Necrotizing [*prevention & control]; 4. Food, Fortified; 5. Infant Formula; 6. Infant, Premature [*growth & development]; 7. Milk; 8. Milk, Human; 9. Randomized Controlled Trials as Topic; 10. Sepsis [prevention & control];
MESH terms:
Intranasal corticosteroids for non‐allergic rhinitis
1. Administration, Intranasal; 2. Adrenal Cortex Hormones [*administration & dosage, *therapeutic use]; 3. Nasal Sprays; 4. Randomized Controlled Trials as Topic; 5. Rhinitis [*drug therapy];
MESH terms:
Interventions to reduce Staphylococcus aureus in the management of eczema
1. *Drug Resistance, Bacterial; 2. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 3. Dermatologic Agents [therapeutic use]; 4. Eczema [drug therapy, *microbiology]; 5. Randomized Controlled Trials as Topic; 6. Staphylococcal Infections [*drug therapy]; 7. Staphylococcus aureus;
MESH terms:
Stopping enteral feeds for prevention of transfusion‐associated necrotising enterocolitis in preterm infants
1. Enteral Nutrition [*methods]; 2. Enterocolitis, Necrotizing [etiology, *prevention & control]; 3. Erythrocyte Transfusion [adverse effects]; 4. Infant, Premature [*growth & development]; 5. Infant, Premature, Diseases [etiology, prevention & control]; 6. Infant, Very Low Birth Weight [growth & development]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Medical and surgical interventions for the treatment of urinary stones in children
1. Adrenergic alpha‐Antagonists [*therapeutic use]; 2. Lasers, Solid‐State [therapeutic use]; 3. Length of Stay; 4. Lithotripsy [adverse effects, *methods]; 5. Nephrolithiasis [*therapy]; 6. Randomized Controlled Trials as Topic; 7. Ureterolithiasis [*therapy]; 8. Ureteroscopy [adverse effects, *methods];
MESH terms:
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy
1. Botulinum Toxins, Type A [*therapeutic use]; 2. Cerebral Palsy [complications, *drug therapy]; 3. Leg; 4. Muscle Spasticity [*drug therapy, etiology]; 5. Neuromuscular Agents [*therapeutic use];
MESH terms:
Valproate for acute mania
1. Antimanic Agents [*therapeutic use]; 2. Bipolar Disorder [*psychology]; 3. Mood Disorders [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Valproic Acid [*therapeutic use];
MESH terms:
Antioxidant supplementation for lung disease in cystic fibrosis
1. Administration, Inhalation; 2. Administration, Oral; 3. Antioxidants [*therapeutic use]; 4. Ascorbic Acid [therapeutic use]; 5. Cystic Fibrosis [*drug therapy]; 6. Micronutrients [*therapeutic use]; 7. Oxidative Stress; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Selenium [therapeutic use]; 11. Vitamin E [therapeutic use]; 12. Vitamins [therapeutic use];
MESH terms:
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [*adverse effects, therapeutic use]; 3. Adrenergic beta‐2 Receptor Agonists [administration & dosage, *adverse effects]; 4. Anti‐Asthmatic Agents [administration & dosage, *adverse effects, therapeutic use]; 5. Asthma [*drug therapy]; 6. Drug Therapy, Combination; 7. Formoterol Fumarate [*adverse effects, therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Interventions to improve disposal of child faeces for preventing diarrhoea and soil‐transmitted helminth infection
1. *Sanitation; 2. Controlled Before‐After Studies; 3. Diarrhea [*parasitology]; 4. Feces; 5. Helminthiasis [*prevention & control, *transmission]; 6. Helminths; 7. Randomized Controlled Trials as Topic; 8. Soil [*parasitology];
MESH terms:
Conservative interventions for treating functional daytime urinary incontinence in children
1. *Biofeedback, Psychology; 2. *Quality of Life; 3. Diurnal Enuresis [*therapy]; 4. Electric Stimulation Therapy [methods]; 5. Exercise Therapy [methods]; 6. Randomized Controlled Trials as Topic; 7. Urinary Incontinence [*therapy]; 8. Urinary Incontinence, Stress [therapy];
MESH terms:
Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy
1. Calcium, Dietary [*administration & dosage]; 2. Dietary Supplements; 3. Hypertension [*prevention & control]; 4. Pre‐Eclampsia [*prevention & control]; 5. Pregnancy Complications, Cardiovascular [*prevention & control]; 6. Premature Birth [prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas
1. Anthelmintics [*therapeutic use]; 2. Body Weight; 3. Child Development [drug effects]; 4. Cognition; 5. Endemic Diseases; 6. Helminthiasis [*drug therapy]; 7. *Intestinal Diseases, Parasitic [complications, drug therapy]; 8. *Nutritional Status; 9. Public Health; 10. Randomized Controlled Trials as Topic; 11. Soil [*parasitology]; 12. *Weight Gain;
MESH terms:
Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis
1. Administration, Oral; 2. Anti‐Inflammatory Agents, Non‐Steroidal [administration & dosage, *therapeutic use]; 3. Cystic Fibrosis [*drug therapy]; 4. Ibuprofen [administration & dosage, therapeutic use]; 5. Piroxicam [administration & dosage, therapeutic use]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Respiratory muscle training in children and adults with neuromuscular disease
1. Breathing Exercises [*methods]; 2. Exhalation [physiology]; 3. Muscle Weakness; 4. Neuromuscular Diseases [*rehabilitation]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Vital Capacity;
MESH terms:
Homeopathy for treatment of irritable bowel syndrome
1. Constipation [etiology, therapy]; 2. Dietary Fiber [therapeutic use]; 3. Homeopathy [*methods]; 4. Irritable Bowel Syndrome [*therapy]; 5. Phytotherapy [*methods]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Altering the availability or proximity of food, alcohol, and tobacco products to change their selection and consumption
1. *Food Supply; 2. *Public Health; 3. Alcoholic Beverages [*supply & distribution]; 4. Environment; 5. Noncommunicable Diseases [*prevention & control]; 6. Restaurants; 7. Schools; 8. Tobacco Products [*supply & distribution]; 9. Workplace;
MESH terms:
Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
1. *Lung Diseases [drug therapy, microbiology]; 2. Aminoglycosides [administration & dosage, *therapeutic use]; 3. Anti‐Bacterial Agents [administration & dosage, *therapeutic use]; 4. Cystic Fibrosis [complications, *drug therapy]; 5. Drug Administration Schedule; 6. Drug Therapy, Combination [methods]; 7. Forced Expiratory Volume [drug effects]; 8. Injections, Intravenous; 9. Pseudomonas Infections [drug therapy]; 10. Pseudomonas aeruginosa; 11. Randomized Controlled Trials as Topic; 12. Vital Capacity [drug effects];
MESH terms:
Fetal biometry for guiding the medical management of women with gestational diabetes mellitus for improving maternal and perinatal health
1. Biometry [*methods]; 2. Diabetes, Gestational [*therapy]; 3. Fetal Macrosomia [*prevention & control]; 4. Insulin [therapeutic use]; 5. Pregnancy Complications [*prevention & control]; 6. Pregnancy Outcome; 7. Randomized Controlled Trials as Topic;
MESH terms:
Chlorhexidine bathing of the critically ill for the prevention of hospital‐acquired infection
1. *Critical Illness; 2. Anti‐Infective Agents, Local [*therapeutic use]; 3. Baths; 4. Central Venous Catheters [adverse effects]; 5. Chlorhexidine [*therapeutic use]; 6. Cross Infection [*prevention & control]; 7. Pneumonia, Ventilator‐Associated [prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Sepsis [prevention & control];
MESH terms:
Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low‐ and moderate‐incidence populations
1. *Contact Tracing; 2. Incidence; 3. Randomized Controlled Trials as Topic; 4. Tuberculosis [*epidemiology];
MESH terms:
Sulthiame add‐on therapy for epilepsy
1. Anticonvulsants [*therapeutic use]; 2. Drug Therapy, Combination; 3. Epilepsy [*drug therapy]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Thiazines [adverse effects, *therapeutic use];
MESH terms:
TNF‐α blockers for the treatment of Kawasaki disease in children
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Immunologic Factors; 3. Mucocutaneous Lymph Node Syndrome [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Tumor Necrosis Factor-alpha [*antagonists & inhibitors]; 6. Vasculitis [drug therapy];
MESH terms:
Prebiotics for the prevention of hyperbilirubinaemia in neonates
1. Hyperbilirubinemia, Neonatal [*prevention & control]; 2. Infant, Premature; 3. Infant, Premature, Diseases [prevention & control]; 4. Phototherapy [methods]; 5. Prebiotics [*administration & dosage]; 6. Randomized Controlled Trials as Topic;
MESH terms:
eHealth interventions for people with chronic kidney disease
1. Disease Progression; 2. Medication Adherence; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Reminder Systems; 6. Renal Insufficiency, Chronic [*mortality]; 7. *Telemedicine;
MESH terms:
Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease
1. Azathioprine [*therapeutic use]; 2. Crohn Disease [*drug therapy, prevention & control, surgery]; 3. Immunosuppressive Agents [*therapeutic use]; 4. Maintenance Chemotherapy [*methods]; 5. Mercaptopurine [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Remission Induction [methods]; 8. Secondary Prevention;
MESH terms:
Protein hydrolysate versus standard formula for preterm infants
1. *Infant Formula; 2. Infant Nutritional Physiological Phenomena [*physiology]; 3. Infant, Premature [*growth & development]; 4. Protein Hydrolysates [*administration & dosage, metabolism]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing obesity in children
1. Behavior Therapy; 2. Body Mass Index; 3. Combined Modality Therapy; 4. *Diet; 5. Exercise [*physiology]; 6. Overweight [prevention & control, therapy]; 7. Pediatric Obesity [*prevention & control, therapy]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Treatment Outcome;
MESH terms:
Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children
1. *Critical Illness; 2. Critical Care; 3. Fluid Therapy [*methods]; 4. Hospital Mortality; 5. Randomized Controlled Trials as Topic; 6. Rehydration Solutions; 7. Saline Solution [*therapeutic use];
MESH terms:
Community first responders for out‐of‐hospital cardiac arrest in adults and children
1. *Emergency Medical Services; 2. *Emergency Responders; 3. Cardiopulmonary Resuscitation [*methods]; 4. Electric Countershock; 5. Out‐of‐Hospital Cardiac Arrest [mortality, *therapy]; 6. Quality of Health Care; 7. Randomized Controlled Trials as Topic; 8. Survival Analysis;
MESH terms:
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Carbamazepine [adverse effects, *therapeutic use]; 3. Epilepsy [*drug therapy]; 4. Phenytoin [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Remission Induction; 7. Seizures [prevention & control]; 8. Treatment Failure; 9. Treatment Outcome;
MESH terms:
Genetic testing for prevention of severe drug‐induced skin rash
1. Exanthema [*genetics, *prevention & control]; 2. Genetic Testing; 3. Randomized Controlled Trials as Topic; 4. Stevens-Johnson Syndrome [genetics, prevention & control];
MESH terms:
Interventions for morphea
1. Methotrexate [adverse effects, therapeutic use]; 2. Phototherapy [*methods]; 3. Prednisone [adverse effects, therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Scleroderma, Localized [*therapy];
MESH terms:
Singing as an adjunct therapy for children and adults with cystic fibrosis
1. Cystic Fibrosis [*therapy]; 2. Music Therapy [*methods]; 3. Randomized Controlled Trials as Topic;
MESH terms:
Inositol in preterm infants at risk for or having respiratory distress syndrome
1. Bronchopulmonary Dysplasia [prevention & control]; 2. Dietary Supplements; 3. Enterocolitis, Necrotizing [prevention & control]; 4. Infant, Premature; 5. Inositol [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Respiratory Distress Syndrome, Newborn [*drug therapy, mortality]; 8. Retinopathy of Prematurity [prevention & control]; 9. Sepsis [prevention & control]; 10. Vitamin B Complex [*therapeutic use];
MESH terms:
Interventions for treating neuropathic pain in people with sickle cell disease
1. Analgesics [*therapeutic use]; 2. Anemia, Sickle Cell [*complications]; 3. Neuralgia [*drug therapy, *etiology]; 4. Pregabalin [*therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Inhaled corticosteroids for cystic fibrosis
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [administration & dosage, adverse effects, *therapeutic use]; 3. Anti-Inflammatory Agents [administration & dosage, adverse effects, *therapeutic use]; 4. Cystic Fibrosis [*drug therapy]; 5. Forced Expiratory Volume [drug effects]; 6. Randomized Controlled Trials as Topic; 7. Vital Capacity;
MESH terms:
Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants
1. Anti‐Ulcer Agents [therapeutic use]; 2. Enterocolitis, Necrotizing [prevention & control]; 3. Gastrointestinal Hemorrhage [*drug therapy, *prevention & control]; 4. Histamine H2 Antagonists [therapeutic use]; 5. Proton Pump Inhibitors [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Sucralfate [therapeutic use];
MESH terms:
Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia
1. Age Factors; 2. *Cell Phone; 3. *Chelation Therapy; 4. Disease Management; 5. Iron Overload [*drug therapy]; 6. *Medication Adherence; 7. Thalassemia [*therapy]; 8. *Therapy, Computer-Assisted;
MESH terms:
Banked preterm versus banked term human milk to promote growth and development in very low birth weight infants
1. *Infant, Premature [growth & development]; 2. *Infant, Very Low Birth Weight; 3. *Milk Banks; 4. Milk, Human; 5. Randomized Controlled Trials as Topic;
MESH terms:
Surgery for epilepsy
1. Analysis of Variance; 2. Anticonvulsants [therapeutic use]; 3. Epilepsies, Partial [drug therapy, *surgery]; 4. Hippocampus [surgery]; 5. Prognosis; 6. Randomized Controlled Trials as Topic; 7. Retrospective Studies; 8. Treatment Outcome;
MESH terms:
Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B
1. Antiviral Agents [adverse effects, *therapeutic use]; 2. DNA, Viral [analysis]; 3. Hepatitis B e Antigens [blood]; 4. Hepatitis B virus [genetics]; 5. Hepatitis B, Chronic [*drug therapy, virology]; 6. Plants, Medicinal [adverse effects, *chemistry]; 7. Randomized Controlled Trials as Topic [statistics & numerical data]; 8. Sophora [adverse effects, *chemistry];
MESH terms:
Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years
1. *Attention Deficit Disorder with Hyperactivity [therapy]; 2. *Behavior Therapy; 3. *Social Skills; 4. Cognitive Behavioral Therapy; 5. Interpersonal Relations;
MESH terms:
Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease
1. *Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; 2. *Crohn Disease [drug therapy, surgery]; 3. *Mesalamine [therapeutic use]; 4. Administration, Oral; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Recurrence;
MESH terms:
Probiotics for preventing acute otitis media in children
1. Acute Disease; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Disease Susceptibility; 4. Otitis Media [epidemiology, *prevention & control]; 5. Probiotics [adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic [statistics & numerical data];
MESH terms:
Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I
1. *Enzyme Replacement Therapy [methods]; 2. *Iduronidase [therapeutic use]; 3. *Mucopolysaccharidosis I [drug therapy]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic;
MESH terms:
Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth
1. Administration, Inhalation; 2. Adrenal Cortex Hormones [administration & dosage, *pharmacology]; 3. Anti-Asthmatic Agents [administration & dosage, *pharmacology]; 4. Asthma [*drug therapy]; 5. Beclomethasone [administration & dosage, pharmacology]; 6. Body Height [drug effects]; 7. Budesonide [administration & dosage, pharmacology]; 8. Fluticasone [administration & dosage, pharmacology]; 9. Growth [*drug effects]; 10. Metered Dose Inhalers; 11. Randomized Controlled Trials as Topic; 12. Time Factors;
MESH terms:
Lipid emulsions for parenterally fed preterm infants
1. *Infant, Premature [growth & development]; 2. *Parenteral Nutrition [adverse effects]; 3. Bilirubin [blood]; 4. Bronchopulmonary Dysplasia [prevention & control]; 5. Chemical and Drug Induced Liver Injury [etiology, *prevention & control]; 6. Cholestasis [chemically induced, *prevention & control]; 7. Emulsions [administration & dosage, chemistry]; 8. Fish Oils [*administration & dosage]; 9. Plant Oils [*administration & dosage]; 10. Randomized Controlled Trials as Topic [statistics & numerical data]; 11. Retinopathy of Prematurity [prevention & control]; 12. Soybean Oil [*administration & dosage, adverse effects]; 13. Surgical Procedures, Operative; 14. gamma‐Linolenic Acid [*administration & dosage];
MESH terms:
Lipid emulsions for parenterally fed term and late preterm infants
1. *Infant, Premature [growth & development]; 2. *Parenteral Nutrition [adverse effects]; 3. Bilirubin [blood]; 4. Chemical and Drug Induced Liver Injury [diagnosis, etiology, *prevention & control]; 5. Cholestasis [chemically induced, diagnosis, *prevention & control]; 6. Emulsions [adverse effects]; 7. Fish Oils [*administration & dosage]; 8. Olive Oil [administration & dosage]; 9. Phospholipids [adverse effects]; 10. Randomized Controlled Trials as Topic [statistics & numerical data]; 11. Soybean Oil [administration & dosage, *adverse effects, chemistry]; 12. Surgical Procedures, Operative; 13. Term Birth;
MESH terms:
Lithium for acute mania
1. *Antipsychotic Agents [therapeutic use]; 2. *Bipolar Disorder [drug therapy]; 3. *Lithium Compounds [therapeutic use]; 4. Acute Disease; 5. Randomized Controlled Trials as Topic; 6. Valproic Acid [therapeutic use];
MESH terms:
Interventions for promoting participation in shared decision‐making for children and adolescents with cystic fibrosis
1. *Cystic Fibrosis; 2. *Decision Making; 3. *Patient Participation; 4. Self‐Management;
MESH terms:
Ready‐to‐use therapeutic food (RUTF) for home‐based nutritional rehabilitation of severe acute malnutrition in children from six months to five years of age
1. *Food, Formulated; 2. *Weight Gain; 3. Fast Foods; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Severe Acute Malnutrition [*diet therapy, mortality]; 7. Treatment Outcome;
MESH terms:
Enteral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates
1. Anti-Bacterial Agents [therapeutic use]; 2. Enterocolitis, Necrotizing [*drug therapy]; 3. Infant, Premature; 4. Lactoferrin [administration & dosage, *therapeutic use]; 5. Neonatal Sepsis [*drug therapy]; 6. Probiotics [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome;
MESH terms:
Preventive lipid‐based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes
1. Child Development [*physiology]; 2. Dietary Fats [*administration & dosage]; 3. Dietary Supplements; 4. Food, Formulated; 5. Food, Fortified; 6. *Infant Nutritional Physiological Phenomena; 7. *Nutritional Status;
MESH terms:
Family therapy approaches for anorexia nervosa
1. Anorexia Nervosa [*therapy]; 2. Body Weight; 3. Family Therapy [*methods]; 4. Psychotherapy [*methods]; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Probiotics for the prevention of pediatric antibiotic‐associated diarrhea
1. Anti‐Bacterial Agents [*adverse effects, therapeutic use]; 2. Diarrhea [etiology, *prevention & control]; 3. Probiotics [*therapeutic use]; 4. Treatment Outcome;
MESH terms:
MVA85A vaccine to enhance BCG for preventing tuberculosis
1. *BCG Vaccine; 2. HIV Seropositivity [complications, immunology]; 3. Primary Prevention; 4. Randomized Controlled Trials as Topic; 5. Tuberculosis [*prevention & control]; 6. *Tuberculosis Vaccines; 7. Vaccines, DNA;
MESH terms:
Haloperidol discontinuation for people with schizophrenia
1. *Drug‐Related Side Effects and Adverse Reactions; 2. Antipsychotic Agents [*adverse effects, therapeutic use]; 3. Haloperidol [*adverse effects, therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Schizophrenia [drug therapy];
MESH terms:
Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis
1. *Burkholderia cepacia complex; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Burkholderia Infections [*drug therapy]; 4. Cystic Fibrosis [*microbiology]; 5. Disease Eradication;
MESH terms:
Medical treatment for botulism
1. Botulinum Toxins; 2. Botulism [*therapy]; 3. Critical Care [*methods]; 4. Hospitalization; 5. Immunoglobulins; 6. Immunoglobulins, Intravenous [*therapeutic use]; 7. Parenteral Nutrition; 8. Randomized Controlled Trials as Topic; 9. Respiration, Artificial;
MESH terms:
First aid glucose administration routes for symptomatic hypoglycaemia
1. Administration, Oral; 2. Diabetes Complications; 3. Diabetes Mellitus [blood]; 4. First Aid; 5. Glucose [*administration & dosage, therapeutic use]; 6. Hypoglycemia [*drug therapy];
MESH terms:
Home use of interdental cleaning devices, in addition to toothbrushing, for preventing and controlling periodontal diseases and dental caries
1. *Dental Devices, Home Care; 2. Dental Caries [*prevention & control]; 3. Dental Plaque [*prevention & control]; 4. Gingivitis [prevention & control]; 5. Oral Health; 6. Periodontal Diseases [*prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents
1. Anxiety [therapy]; 2. Chronic Pain [*therapy]; 3. Depression [therapy]; 4. Pain Management [*methods]; 5. Psychotherapy [*methods]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Telemedicine [*methods]; 9. Treatment Outcome;